- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
GRAIL, LLC(GRAL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GRAL
11/13/2026: GRAL (3-star) is currently NOT-A-BUY. Pass it for now.
GRAIL, LLC is a commercial-stage healthcare company specializing in multi-cancer early detection via its flagship Galleri blood test. The company's primary strength lies in its pioneering methylation technology and extensive clinical validation data, offering a disruptive growth story in preventative oncology. However, key risks include heavy net operating losses, ongoing cash burn, and the challenge of securing broad insurance reimbursement. The stock best suits growth-oriented investors with high risk tolerance who are willing to monitor regulatory progress, test adoption rates, and clinical developments over the long term.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | GRAIL offers high top-line revenue expansion and exposure to disruptive early-stage cancer screening markets. |
| Momentum investor | Strong fit while signal remains positive | The stock experiences notable price momentum driven by clinical updates and market enthusiasm for liquid biopsies. |
| Value investor | Weak fit | The company lacks earnings and trades at negative net margins with high ongoing cash burn. |
| Dividend investor | Weak fit | GRAIL does not pay dividends and retains all earnings to fund research and commercial scaling. |
| Low-risk investor | Weak fit | High price volatility, regulatory uncertainties, and lack of profitability expose risk-averse investors to substantial downside. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock experiences sharp price swings reacting to clinical trial readouts, market sentiment, and healthcare sector trends. |
| Valuation risk | Medium / high | Valuing a pre-profitability genomic pioneer relies heavily on long-term adoption assumptions rather than near-term earnings. |
| Competition risk (liquid biopsy and multi-cancer screening competition) | High | Rivals like Guardant Health and Natera are aggressively developing competing oncology screening tools. |
| Business quality | Medium | Proprietary scientific assets are world-class, but commercialization infrastructure and payer coverage remain works in progress. |
| Dividend income | Low / none | Income-focused investors receive zero cash returns from dividend payouts. |
| Execution risk | High | Success depends heavily on scaling test volume, securing broad insurance reimbursement, and executing regulatory strategies. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.21B USD | Price to earnings Ratio - | 1Y Target Price 139.44 |
Price to earnings Ratio - | 1Y Target Price 139.44 | ||
Volume (30-day avg) 952.2K shares | Beta 2.87 | 52 Weeks Range 41.50 - 166.47 | Updated Date 11/15/2026 |
52 Weeks Range 41.50 - 166.47 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.22 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Diagnostics & Research
- BUY participation
- 68.8%
- Active BUY / eligible
- 11 / 16
- 30-Day BUY Count Change
- 0
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Hockey-Stick Growth
The stock demonstrates a Hockey-Stick Growth price path pattern.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 481.44% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Multi-Cancer Early Detection Testing | Commercial laboratory processing and analysis fees generated from the Galleri blood screening test ordered by physicians. | The company primarily earns revenue each time a patient takes its proprietary blood test to screen for hidden cancers. |
| Research and Development Services | Collaborative clinical development programs and genomic sequencing services provided to biopharmaceutical partners. | Secondary income is derived from scientific partnerships and clinical validation research projects. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 1.11 | Enterprise Value 4.51B | Price to Sales(TTM) 31.28 |
Enterprise Value 4.51B | Price to Sales(TTM) 31.28 | ||
Enterprise Value to Revenue 27.06 | Enterprise Value to EBITDA - | Shares Outstanding 44.96M | Shares Floating 34.64M |
Shares Outstanding 44.96M | Shares Floating 34.64M | ||
Percent Insiders 5.06 | Percent Institutions 86.22 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

